Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18745572 | Dry Powdered Compositions and Methods and Uses Thereof | June 2024 | March 2025 | Allow | 9 | 0 | 0 | Yes | No |
| 18608090 | PYRAZOLE DERIVATIVE AND HARMFUL ORGANISM-CONTROLLING AGENT | March 2024 | October 2024 | Allow | 7 | 0 | 0 | No | No |
| 18054767 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | November 2022 | May 2025 | Allow | 30 | 0 | 0 | No | No |
| 17815485 | GRAPHENE BIOSCAFFOLDS AND THEIR USE IN CELLULAR THERAPY | July 2022 | January 2025 | Abandon | 29 | 3 | 0 | No | No |
| 17758877 | GAS-GENERATING MICELLE FOR REDUCING LOCALIZED FAT | July 2022 | May 2024 | Allow | 22 | 2 | 0 | No | No |
| 17757245 | FULVESTRANT PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | June 2022 | April 2025 | Allow | 34 | 1 | 0 | No | No |
| 17804204 | INJECTABLE FORMULATIONS OF APREPITANT | May 2022 | November 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17722490 | STATIC-PROOF WATER-BASED PROTECTIVE FILM AND PREPARATION METHOD THEREOF | April 2022 | March 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17720440 | PROTECTIVE FILM WITH ANTIBACTERIAL PROPERTY, METHOD FOR PREPARING THE SAME, AND PRODUCT HAVING THE SAME | April 2022 | March 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17707969 | HIGHLY COMPRESSIBLE SHAPE MEMORY DOUBLE NETWORK HYDROGEL, USE AND PREPARATION METHOD THEREOF, AND INTERVERTEBRAL DISK SCAFFOLD | March 2022 | November 2024 | Abandon | 32 | 3 | 0 | No | No |
| 17693271 | PROCESS FOR PRODUCING AN ANDROGRAPHOLIDE CARRIER SYSTEM | March 2022 | June 2024 | Allow | 28 | 0 | 0 | No | No |
| 17690084 | CANNABINOID-CONTAINING SKIN CARE COMPOSITIONS | March 2022 | December 2023 | Abandon | 21 | 1 | 0 | No | No |
| 17690794 | HYDROXYQUINOLINE COMPOUNDS AND METHODS OF USE AS PIGMENT MODIFYING AGENTS | March 2022 | March 2025 | Allow | 36 | 3 | 1 | No | No |
| 17689457 | MICROEMULSION MIXTURE AND METHOD OF USING THE SAME, AND PHARMACEUTICAL MICROEMULSION MIXTURE AND METHOD OF USING THE SAME | March 2022 | August 2023 | Allow | 17 | 1 | 0 | No | No |
| 17674598 | PREPARATION OF SOLUBLE FORM OF CURCUMIN | February 2022 | December 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17592656 | NOVEL CRYSTALLINE FORM OF PYROXASULFONE, METHODS FOR ITS PREPARATION AND USE OF THE SAME | February 2022 | December 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17626043 | CANCER CELL-TARGETED DRUG DELIVERY CARRIER AND COMPOSITION FOR PROMOTING PHOTO-THERMAL TREATMENT EFFECTS, BOTH OF WHICH CONTAIN M1 MACROPHAGES AS ACTIVE INGREDIENT | January 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17624836 | A METHOD FOR THE PREPARATION OF A GEL-FORMING COMPOSITION | January 2022 | April 2025 | Abandon | 39 | 4 | 0 | Yes | No |
| 17623805 | COMPOSITIONS AND METHODS FOR TREATING MYOCARDIUM WITH MESENCHYMAL STEM CELL SCAFFOLD | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17620824 | GASTRORETENTIVE DOSAGE FORMS OF LEVODOPA AND CARBIDOPA | December 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17620327 | LIPOSOMAL DOXORUBICIN FORMULATION, METHOD FOR PRODUCING A LIPOSOMAL DOXORUBICIN FORMULATION AND USE OF A LIPOSOMAL DOXORUBICIN FORMULATION AS A MEDICAMENT | December 2021 | May 2025 | Allow | 40 | 2 | 0 | No | No |
| 17644169 | MOISTURIZING COMPOSITION AND METHOD | December 2021 | October 2024 | Abandon | 34 | 3 | 0 | Yes | No |
| 17551062 | Long Chain Fatty Acid Compound Colloidal Sulfur Formulations Comprising Functional Ingredients For Acne Treatment And Other Application | December 2021 | March 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17617134 | COMPOSITIONS AND METHODS FOR IMPROVING WELLNESS | December 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17616992 | THERMOGELLING CANNABINOID COMPOSITION AND METHOD OF MANUFACTURE AND USE THEREOF | December 2021 | February 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17615786 | 1-PHENYL-5-AZINYLPYRAZOLYL-3-OXYALKYL ACIDS AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH | December 2021 | August 2024 | Allow | 32 | 0 | 0 | No | No |
| 17614635 | PHARMACEUTICAL COMPOSITION FOR PROMOTING OSTEOGENESIS, COMPRISING OSTEOBLAST-DERIVED MITOCHONDRIA | November 2021 | March 2025 | Allow | 39 | 2 | 0 | Yes | No |
| 17610962 | COMPOSITIONS COMPRISING LOPINAVIR AND TREATMENT OF CONDITIONS | November 2021 | May 2025 | Allow | 42 | 1 | 1 | No | No |
| 17609384 | MONODISPERSE EMULSIONS TEMPLATED BY THREE-DIMENSIONAL STRUCTURED MICROPARTICLES AND METHODS OF MAKING THE SAME | November 2021 | April 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17518896 | Disinfecting Composition and Related Methods | November 2021 | October 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17519413 | METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES | November 2021 | January 2025 | Abandon | 38 | 2 | 0 | No | Yes |
| 17606008 | GENE EXPRESSION PROMOTER FOR SKIN BEAUTIFICATION | October 2021 | February 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17604592 | MICROCAPSULES CONTAINING CURCUMIN, AND METHODS FOR THE PRODUCTION THEREOF | October 2021 | January 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17603816 | INJECTABLE TRIAMCINOLONE FORMULATIONS | October 2021 | May 2025 | Allow | 43 | 3 | 0 | Yes | No |
| 17476789 | Hair Loss Treatment Composition | September 2021 | February 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17436354 | Edible Film Comprising Adjacent Conjoined Strips | September 2021 | January 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17434990 | NUTRACEUTICAL COMPOSITIONS | August 2021 | December 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17412442 | CANNABINOID AND MENTHOL TRANSDERMAL DELIVERY SYSTEMS AND METHODS | August 2021 | August 2024 | Allow | 36 | 3 | 0 | No | No |
| 17428843 | COMPOSITIONS AND METHODS FOR INHIBITING POST-SURGICAL ADHESIONS | August 2021 | August 2024 | Allow | 37 | 1 | 0 | No | No |
| 17381613 | CANNABINOID STORAGE STABILITY | July 2021 | May 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17419183 | BIOBASED THICKENING COMPOSITION COMPRISING A POLY(FARNESENE) | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17419102 | LIQUID COMPOSITIONS | June 2021 | May 2024 | Abandon | 34 | 2 | 0 | No | No |
| 17335039 | Injectable Temperature-sensitive Composite Hydrogel Containing Adipose-derived Mesenchymal Stem Cells and Preparation Method and Application Thereof | May 2021 | October 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17293495 | ATTRACTANT COMPOSITION FOR THE SPECIES DELOTTOCOCCUS ABERIAE, METHODS FOR THE MONITORING, DETECTION AND/OR CONTROL OF THE PEST | May 2021 | August 2024 | Allow | 39 | 1 | 0 | No | No |
| 17292225 | COMPOSITION FOR STERILIZATION AND CLEANING, METHOD FOR PRODUCING SAME, AND STERILIZATION AND CLEANING METHOD EMPLOYING SAME | May 2021 | March 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17290942 | MANAGEMENT OF RISK OF CATION OVERLOAD AND ELECTROLYTE IMBALANCE WITH TOPICALLY APPLIED BUFFERS | May 2021 | November 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17246883 | COMPOSITION AND PROCESS FOR RECONDITIONING RESPIRATORS AND OTHER PERSONAL PROTECTIVE EQUIPMENT | May 2021 | October 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17240919 | Dry Powdered Compositions and Methods and Uses Thereof | April 2021 | February 2024 | Allow | 33 | 2 | 0 | No | No |
| 17286181 | HEMOSTATIC MATERIAL | April 2021 | July 2025 | Abandon | 51 | 3 | 1 | Yes | No |
| 17222026 | Devices and Methods for Nerve Regeneration | April 2021 | August 2023 | Allow | 28 | 1 | 0 | No | No |
| 17282121 | HYDROGEL COMPOSITIONS | April 2021 | November 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17282069 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | April 2021 | November 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17277423 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | March 2021 | April 2025 | Allow | 49 | 3 | 1 | No | No |
| 17204106 | MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT | March 2021 | October 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17276568 | Medical Use of Honokiol | March 2021 | February 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17270160 | Nanoparticles | February 2021 | October 2023 | Allow | 32 | 0 | 0 | No | No |
| 17170310 | COMPOSITIONS AND METHODS FOR TARGETING ANGIOGENESIS FOR FRACTURE NONUNION TREATMENT UNDER INFLAMMATORY DISEASES | February 2021 | June 2025 | Abandon | 52 | 4 | 0 | Yes | No |
| 17263342 | SYNERGISTICALLY EFFECTIVE HERBICIDE COMPOSITION COMPRISING PYRIDATE AND AT LEAST ONE DEFINED 4-HPPD INHIBITOR | January 2021 | April 2025 | Allow | 51 | 3 | 0 | No | No |
| 17158583 | COLON LAVAGE SYSTEM | January 2021 | January 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17262300 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A THERAPEUTIC AGENT FOR TREATING DEMENTIA AND USES THEREOF | January 2021 | October 2024 | Allow | 45 | 2 | 0 | No | No |
| 17262142 | A NANOPARTICLE FOR RADIATION PROTECTION | January 2021 | August 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17261323 | PROTEIN ENCAPSULATION OF NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS | January 2021 | May 2025 | Abandon | 52 | 3 | 0 | No | No |
| 17257918 | REGENERATION OF TENDON AND TENDON SHEATH, RESTORATION MATERIAL, AND USE OF RESTORATION MATERIAL | January 2021 | October 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 17257973 | URACIL COMPOUND AND USE THEREOF | January 2021 | October 2023 | Allow | 33 | 0 | 0 | No | No |
| 17135194 | OVERPOWERED ABA RECEPTOR AGONISTS | December 2020 | July 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17253731 | PESTICIDALLY ACTIVE ISOXAZOLINE DERIVATIVES CONTAINING AN AMIDE GROUP AND AN AZETIDINE SULFONE GROUP | December 2020 | April 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17253165 | HERBICIDAL COMPOUNDS | December 2020 | August 2023 | Allow | 32 | 0 | 0 | Yes | No |
| 17058854 | WHEY PROTEIN CONCENTRATE IN ASSOCIATION WITH ANTITUMOUR TREATMENT | November 2020 | April 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17250107 | PYRAZOLE DERIVATIVE AND HARMFUL ORGANISM-CONTROLLING AGENT | November 2020 | December 2023 | Allow | 37 | 0 | 1 | No | No |
| 17099077 | COMPOSITIONS AND METHODS FOR ADDRESSING VISION IMPAIRMENT | November 2020 | December 2024 | Abandon | 49 | 5 | 0 | Yes | No |
| 17080983 | NOVEL CLOTHIANIDIN COMPOSITIONS AND METHODS OF USE THEREOF | October 2020 | May 2023 | Allow | 30 | 1 | 0 | No | No |
| 16966278 | COMPOSITION FOR BONE GRAFTING, COMPRISING NUCLEIC ACIDS, BONE GRAFT MATERIAL AND CATIONIC POLYMER, AND BONE GRAFT KIT FOR MANUFACTURING SAME | October 2020 | June 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17046909 | OIL-BASED SUSPENSION CONCENTRATES | October 2020 | December 2023 | Abandon | 38 | 2 | 0 | No | No |
| 17046889 | SOLID FORMULATION OF INSECTICIDAL MIXTURES | October 2020 | December 2024 | Allow | 50 | 5 | 0 | Yes | No |
| 17046477 | SOLID FORMULATION OF INSECTICIDAL MIXTURES | October 2020 | August 2024 | Allow | 46 | 3 | 0 | Yes | No |
| 17045010 | INCREASING WATER RETENTION IN SOIL TO MITIGATE DROUGHT | October 2020 | April 2025 | Allow | 54 | 3 | 0 | Yes | No |
| 17040833 | FUNGICIDAL COMBINATIONS | September 2020 | October 2024 | Abandon | 48 | 4 | 1 | Yes | No |
| 16992857 | TISSUE REPAIR MEMBRANE ADAPTED FOR ADHESION AND LUBRICATION, AND METHODS FOR PREPARING THE SAME | August 2020 | June 2025 | Allow | 58 | 5 | 0 | Yes | No |
| 16966990 | HERBICIDAL MIXTURES | August 2020 | October 2023 | Abandon | 39 | 2 | 0 | No | No |
| 16960413 | ALGINATE ENCAPSULATION OF FUNGAL MICROSCLEROTIA | July 2020 | August 2024 | Abandon | 49 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KWON, JOHN SEUNGJAI.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KWON, JOHN SEUNGJAI works in Art Unit 1615 and has examined 78 patent applications in our dataset. With an allowance rate of 44.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner KWON, JOHN SEUNGJAI's allowance rate of 44.9% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KWON, JOHN SEUNGJAI receive 1.69 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KWON, JOHN SEUNGJAI is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +28.3% benefit to allowance rate for applications examined by KWON, JOHN SEUNGJAI. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 28.6% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 111.1% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.7% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.